论文部分内容阅读
1995～ 1998三年中 ,对绝经期骨质疏松 (MOP) 111例进行为期 2年的前瞻性雌激素替代治疗 (HRT)研究 ,其中 56人应用利维爱 (Livial)为研究组 ,55人应用尼尔雌醇为对照组 ,经过 2年随诊 ,终点结论是 HRT对缓解更年期症状 ,提高患者生活质量 ,增加骨密度 (BMD)都有效果 ,但研究组明显优于对照组 ,具有统计学意义。 HRT的副作用为出血 :治疗组 5.35% ,对照组 10 .9% ,乳房胀痛 :治疗组7.14% ,对照组 9.0 9%。经济承受力差 ,中途退出治疗组 8.92 % ,对照组 3.6 3%。从而证实 L ivial作为HRT,对 MOF治疗的正作用强 ,副作用少 ,是 HRT首选药 ,今后如能降低药价 ,更适合我国医疗改革的国情 ,使患者经济承受力能够接受 ,将会在更多 MOR治疗中起到积极作用。
In the three years from 1995 to 1998, 111 prospective menopausal osteoporosis (MOP) patients underwent 2 years of prospective estrogen replacement therapy (HRT), of which 56 were treated with Livial and 55 Application of nilestriol as control group, after 2 years of follow-up, the end of the conclusion is that HRT to ease menopausal symptoms, improve patient quality of life, increase bone mineral density (BMD) have effect, but the study group was significantly better than the control group, with statistics Significance of learning. The side effects of HRT were bleeding: 5.35% in the treatment group, 10.9% in the control group, and breast tenderness: 7.14% in the treatment group and 9.09% in the control group. Poor economic affordability, quit the treatment group 8.92% midway, control group 3.6 3%. Thus confirmed Livial as HRT, positive for MOF treatment, less side effects, is the preferred drug for HRT, future if it can reduce drug prices, more suitable for the national conditions of China’s medical reform, so that patients can afford the economic viability will be more Multi-MOR treatment has played a positive role.